📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
214 analysed today
FollowTelegram
214
Today
152,076
All-time analysed
43,619
Positive
6,746
Negative
92,864
Neutral
8,779
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
848 announcements match the current filters (relevance ≥ 5).
OnMobile to Launch ONMO+ Smart Console on Flipkart on June 26, 2026
OnMobile Global Limited has announced the official launch of its ONMO+ Smart Console on Flipkart, scheduled for June 26, 2026, at 12:00 PM IST. The product aims to democratize premium gaming by enabling Console and PC gaming on Smart TVs, tablets, and phones using a specialized controller and access card. This move eliminates the need for expensive traditional gaming hardware, potentially expanding the company's addressable market in the gaming sector. Investors should note this strategic shift towards a hardware-integrated gaming ecosystem.
Key Highlights
Official launch of ONMO+ Smart Console scheduled for June 26, 2026, at 12:00 PM IST
Product will be available for purchase through a strategic partnership with Flipkart
Enables high-end Console/PC gaming on Smart TVs, tablets, and phones without additional hardware
Combines a pro gaming controller with an instant-access card for a seamless user experience
👀 What to Watch
Investors should monitor the initial sales traction on Flipkart and look for management commentary on the revenue model and margin profile of this new product line. Watch for the detailed press release on June 26 for pricing and subscription details.
Ambica Agarbathies to Raise ₹2.12 Cr via Preferential Issue of 8.48 Lakh Shares at ₹25/Share
Ambica Agarbathies & Aroma Industries Limited has issued a corrigendum for its upcoming EGM on June 30, 2026, regarding a preferential issue of 8,48,600 equity shares. The shares are priced at ₹25 each, which is higher than the SEBI-mandated floor price of ₹24.86. The total proceeds of approximately ₹2.12 crore will be utilized for working capital requirements within three months of allotment. Post-issue, the four proposed allottees will collectively hold a 4.708% stake in the company.
Key Highlights
Preferential issue of 8,48,600 equity shares at a fixed price of ₹25 per share.
Total fundraise of ₹2,12,15,000 intended for working capital needs.
Issue price set above the 90-day VWAP of ₹24.86 and 10-day VWAP of ₹23.54.
Four individual allottees to acquire a combined 4.708% post-issue equity stake.
Corrigendum issued to comply with specific disclosure requirements from NSE and BSE.
👀 What to Watch
Investors should note the capital infusion intended for operations and monitor the EGM results on June 30 to confirm shareholder approval for the dilution.
Bigbloc Construction FY26 Revenue Rises 26% to ₹283 Cr; Sales Volume Reaches 8.19 Lakh CBM
Bigbloc Construction reported a 26% YoY revenue increase to ₹2,834 million for FY26, supported by a volume growth of 36% in AAC blocks. Despite the top-line growth, EBITDA margins dropped significantly to 6.21% from 13.00% in FY25, suggesting increased input costs or competitive pricing pressures. The company has achieved a total capacity of 1.3 million CBM p.a. and is expanding into central India with land acquisition in Madhya Pradesh. With a 5-year revenue CAGR of 22%, the company remains a key player in the eco-friendly building materials segment.
Key Highlights
FY26 Revenue grew to ₹2,834 million from ₹2,246 million in FY25, a 26% increase.
Sales volume for AAC blocks increased to 819,175 CBM in FY26, up from 600,773 CBM YoY.
EBITDA margin contracted sharply to 6.21% in FY26, down from 13.00% in the previous fiscal.
Total manufacturing capacity reached 13,00,000 CBM p.a. across four state-of-the-art units.
Net Debt to Equity ratio stands at 1.4x with a 5-year revenue CAGR of 22%.
👀 What to Watch
While volume growth is robust, the sharp decline in margins is a concern that requires further investigation into cost structures. Investors should monitor management's strategy for margin recovery before making new commitments.
Biocon Announces Re. 0.50 Final Dividend for FY26; Details TDS Procedures
Biocon Limited has recommended a final dividend of Re. 0.50 per equity share (10% of face value) for the financial year ended March 31, 2026. The dividend is subject to shareholder approval at the Annual General Meeting scheduled for August 06, 2026. The company has set July 03, 2026, as the record date to determine eligible shareholders. The announcement primarily focuses on the Tax Deducted at Source (TDS) requirements, outlining rates ranging from 0% to 20% based on residency and documentation provided by July 20, 2026.
Key Highlights
Recommended final dividend of Re. 0.50 per equity share (10% of face value) for FY 2025-26.
Record date for dividend eligibility is fixed as Friday, July 03, 2026.
Standard TDS rate of 10% for resident shareholders with valid PAN and 20% for those without.
Individual resident shareholders are exempt from TDS if the total dividend does not exceed Rs. 10,000.
Deadline for submitting tax-related documents and declarations is Monday, July 20, 2026.
👀 What to Watch
Shareholders should ensure their PAN and bank account details are updated with their Depository Participant or RTA by the record date and submit necessary tax forms by July 20 to avoid higher TDS.
Birla Corp Commences Commercial Production at Bikram Coal Mine in Madhya Pradesh
Birla Corporation Limited has announced the commencement of commercial production at its Bikram Coal Mine, located in Shahdol, Madhya Pradesh, effective June 22, 2026. This follows the initial start of mining operations reported on April 23, 2026. The transition to commercial production is a significant operational milestone that aims to enhance the company's fuel security for its cement manufacturing operations. The production officially began at approximately 1:45 p.m. IST on the date of the announcement.
Key Highlights
Commercial production at Bikram Coal Mine started on June 22, 2026, at 1:45 p.m. IST.
The mine is situated in Burhar, Shahdol district, Madhya Pradesh.
This follows the earlier commencement of mining operations announced on April 23, 2026.
The move is expected to improve backward integration and reduce reliance on external coal sources.
👀 What to Watch
Investors should monitor the impact of this captive coal source on the company's power and fuel costs in upcoming quarterly earnings. This development strengthens the company's margin profile through better cost control.
BIL Vyapar Limited Schedules 14th Committee of Creditors (CoC) Meeting
BIL Vyapar Limited, formerly known as Binani Industries Limited, has announced its 14th Committee of Creditors (CoC) meeting scheduled for June 22, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code. This meeting is a critical step in the ongoing resolution process to determine the company's future and debt restructuring. The disclosure is made in compliance with Regulation 30 of SEBI (LODR) Regulations.
Key Highlights
The 14th meeting of the Committee of Creditors (CoC) is convened for June 22, 2026.
Company is currently under the Corporate Insolvency Resolution Process (CIRP).
BIL Vyapar Limited was formerly known as Binani Industries Limited (Scrip Code: 500059).
Disclosure follows requirements of Para 16(g) of Part A of Schedule III of SEBI LODR.
👀 What to Watch
Investors should remain cautious as the company is in insolvency; equity value is at high risk of being significantly diluted or extinguished depending on the approved resolution plan.
Concord Biotech to Acquire 27.38% Stake in FSGE Renewable for Rs 6.3 Crore
Concord Biotech has entered into an agreement to acquire a 27.38% equity stake in FSGE Renewable Power Private Limited for a cash consideration of Rs 6.3 Crores. This strategic investment is aimed at setting up a hybrid renewable energy plant in Gujarat with 6.3 MW Wind and 6.3 MWp Solar capacity. The project will serve as a captive power source for the company's Limbasi facility, focusing on long-term reduction of energy costs. FSGE is currently a Special Purpose Vehicle (SPV) and is expected to allot shares within 60 days.
Key Highlights
Acquisition of 27.38% equity stake in FSGE Renewable Power for Rs 6.3 Crores in cash.
Installation of a hybrid power project with 6.3 MW Wind and 6.3 MWp Solar capacity in Gujarat.
The project is dedicated to providing captive power for the company's Limbasi manufacturing facility.
Investment aims to reduce the company's carbon footprint and lower long-term operational energy costs.
FSGE is an SPV incorporated in August 2023 and has not yet commenced commercial operations.
👀 What to Watch
Investors should view this as a positive step toward operational efficiency and ESG compliance which may improve margins over the long term. Monitor the project's completion timeline and its impact on power cost savings in future earnings reports.
Hester Biosciences Sets July 14 as Record Date for INR 11 Per Share Final Dividend
Hester Biosciences Limited has fixed July 14, 2026, as the record date to determine shareholder eligibility for a final dividend of INR 11 per equity share for the financial year. This dividend represents a 110% payout on the face value of INR 10 per share. The distribution is subject to shareholder approval at the company's 39th Annual General Meeting. The record date also serves as the cutoff for determining members entitled to participate in e-voting for the AGM.
Key Highlights
Record date for dividend and AGM e-voting fixed for July 14, 2026.
Proposed final dividend of INR 11 per equity share (110% of face value).
Face value of the company's equity shares is INR 10 each.
Dividend payout is subject to approval at the 39th Annual General Meeting and applicable tax deductions.
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date, which typically precedes the July 14 record date. Monitor the 39th AGM outcomes for final dividend declaration and payment timelines.
Hester Biosciences FY26 Consolidated PAT Surges 99% to ₹574.8M; AGM Set for July 21
Hester Biosciences reported a robust financial performance for FY 2025-26, with consolidated profit after tax (PAT) jumping 99% to ₹574.84 million despite a modest 7% revenue growth to ₹3,325.99 million. The company achieved significant margin expansion, with standalone EBITDA rising 56% to ₹871.03 million, driven by a favorable product mix and cost discipline. Key operational milestones include the commercialization of the H9N2 Avian Influenza vaccine and the repurposing of the BSL-3 facility for veterinary use. The company has scheduled its 39th AGM for July 21, 2026, and confirmed a dividend payout ratio of 18%.
Key Highlights
Consolidated PAT grew by 99% YoY to ₹574.84 million, while Standalone PAT rose 64% to ₹521 million.
Poultry Healthcare division recorded a strong 24% growth, supported by the launch of the H9N2 Avian Influenza vaccine.
Standalone EBITDA increased by 56% to ₹871.03 million, reflecting improved operational efficiencies.
The company capitalized its Fill-Finish and BSL-3 facilities, enhancing manufacturing scale-up capabilities.
Final dividend payment is scheduled on or after July 28, 2026, for shareholders as of the July 14 cut-off date.
👀 What to Watch
Investors should note the significant improvement in profitability and margins, suggesting successful cost management and a shift toward higher-margin products. The stock warrants a positive outlook given the successful commercialization of new vaccines and the operational readiness of advanced BSL-3 facilities.
SBI Board Approves Raising Up To ₹60,000 Crore via Debt Instruments for FY27
The Central Board of State Bank of India has approved a significant fund-raising plan of up to ₹60,000 Crore for the financial year 2026-27. The capital will be raised through various debt instruments, including Long Term Bonds and Basel III compliant Additional Tier 1 and Tier 2 Bonds. These funds can be sourced in INR or other convertible currencies from both Indian and overseas investors. This move is aimed at strengthening the bank's capital base to support credit growth and maintain regulatory capital adequacy ratios.
Key Highlights
Approved fundraise of up to ₹60,000 Crore for the financial year 2026-27.
Instruments include Long Term Bonds and Basel III compliant AT1 and Tier 2 Bonds.
Funds to be raised via public offer or private placement in INR or foreign currencies.
Issuance is subject to Government of India approval where required.
The board meeting concluded at 1:15 pm on June 18, 2026.
👀 What to Watch
Investors should view this as a proactive step to fuel future loan growth and strengthen the balance sheet; monitor the pricing and timing of these bond issuances for impact on margins.
Birla Corp Subsidiary RCCPL's INR 17,180M Bank Loan Rating Affirmed at IND AA/Stable
Birla Corporation Limited's wholly-owned material subsidiary, RCCPL Private Limited, has had its credit rating affirmed by India Ratings & Research. The rating for bank loan facilities totaling INR 17,180 million remains at 'IND AA' with a Stable outlook. This affirmation covers various term loans from major lenders including Punjab National Bank, HDFC Bank, and Indian Bank, signaling continued financial stability for the group's core cement operations.
Key Highlights
India Ratings affirmed the 'IND AA/Stable' rating for RCCPL Private Limited's bank loan facilities.
The total size of the rated bank loan facilities is INR 17,180 million.
Major loan components include INR 9,292.4 million from Punjab National Bank and INR 2,867.5 million from HDFC Bank.
The rating action is an affirmation, indicating no change in the subsidiary's credit risk profile.
RCCPL Private Limited is a material subsidiary, making its credit health vital for Birla Corporation's consolidated balance sheet.
👀 What to Watch
No immediate action is required as the credit rating affirmation indicates status quo on the company's debt-servicing capability. Investors should monitor the company's quarterly interest coverage ratios to ensure the 'Stable' outlook remains justified.
India Ratings Affirms Birla Corp’s ‘IND AA/Stable’ Rating; Assigns Rating to New INR 120 Cr Facility
India Ratings has affirmed Birla Corporation's 'IND AA' rating with a stable outlook, citing its strong market position and improved financial profile. In FY26, the company saw its EBITDA grow 19% YoY to INR 14.5 billion, while net leverage improved significantly to 1.4x from 1.8x in FY25. The company is embarking on a major expansion phase with a planned capex of INR 50-60 billion through FY30 to increase capacity by 30%. Liquidity remains adequate with INR 12.1 billion in cash equivalents against FY27 repayments of INR 6.7 billion.
Key Highlights
Affirmed 'IND AA/Stable' rating for INR 3,781.50 million and assigned the same for new INR 1,203.40 million bank facilities.
Consolidated EBITDA increased to INR 14.5 billion in FY26 with margins improving to 15.1% from 13.2% YoY.
Net leverage (Net Debt/EBITDA) reduced to 1.4x in FY26, down from 2.1x in FY24, reflecting strong debt management.
Announced a phased capacity expansion of 6.2 mtpa (30% of current capacity) with a total investment of INR 50-60 billion by FY30.
Maintained a high capacity utilization rate of 95% in FY26, significantly outperforming the industry average of 65%-70%.
👀 What to Watch
Investors should take confidence in the company's deleveraging trend and high operational efficiency. While the upcoming large-scale capex may increase leverage temporarily, the stable rating outlook suggests the company has sufficient cash flow and balance sheet strength to manage the expansion.
IFB Industries Q4 FY26 PAT Jumps 51% to ₹33.7 Cr; Revenue Up 11% YoY
IFB Industries reported a steady Q4 FY26 with revenue growing 11.03% YoY to ₹1,456 crores, driven by strong double-digit growth in front-load and top-load washing machines. Net profit for the quarter rose significantly by 51% to ₹33.72 crores, despite an exceptional charge related to new labor codes. The company is actively simplifying its product portfolio to improve manufacturing efficiency and focus on premiumization, including upcoming launches in the 13kg-14kg segment. Management successfully mitigated ₹67 crores of the ₹84 crores total impact from adverse forex and commodity price movements through cost optimization.
Key Highlights
Q4 FY26 Revenue grew 11.03% YoY to ₹1,456 crores, while PAT increased 51% to ₹33.72 crores.
Front-load washing machine segment saw a robust 21% volume growth in the fourth quarter.
Cost optimization initiatives recovered ₹67 crores out of an ₹84 crores hit from commodity and forex volatility.
Company plans to launch 13kg and 14kg front loaders to target the high-growth premium segment.
FY26 total capex stood at ₹89 crores, with ₹43 crores dedicated to the Home Appliances division.
👀 What to Watch
Investors should monitor the success of the product rationalization strategy and the upcoming premium launches, as these are expected to drive margin expansion. The company's ability to offset macro headwinds through internal cost controls is a positive sign for long-term profitability.
Concord Biotech Completes ANVISA Inspection at Limbasi API Facility
Concord Biotech Limited has successfully completed an inspection by the Brazilian Health Regulatory Agency (ANVISA) at its Limbasi API manufacturing facility. The inspection was conducted over five days from June 8 to June 12, 2026. This successful outcome is a key milestone for the company's international expansion, facilitating entry into the large Brazilian pharmaceutical market. It reinforces the company's global regulatory footprint and adherence to high-quality manufacturing standards.
Key Highlights
Successful completion of ANVISA inspection at the Limbasi API manufacturing facility.
Inspection conducted by the Brazilian Health Regulatory Agency from June 8 to June 12, 2026.
Enhances access to the Brazilian pharmaceutical market, one of the largest in the world.
Strengthens the company's global manufacturing and regulatory footprint for its API business.
👀 What to Watch
Investors should view this as a positive regulatory development that paves the way for revenue growth in the Latin American region. Monitor for future product filings and approvals in the Brazilian market following this facility clearance.
Biocon to Acquire 15.91% Stake in Ampin C&I Power Twelve for ₹5.48 Crore
Biocon Limited has invested ₹5.48 crore to acquire an equity stake in Ampin C&I Power Twelve Private Limited (AMPIN), a special purpose vehicle for solar power generation. The company is subscribing to 54.76 lakh equity shares at ₹10 each, initially holding a 37.77% stake which will dilute to 15.91% upon further investments by other partners. This strategic move is designed to secure captive solar power for its Karnataka operations, aiming to reduce energy costs and meet decarbonization targets. AMPIN is a newly incorporated entity setting up a 27.12 MW solar plant with a net worth of ₹12.08 crore as of March 2026.
Key Highlights
Investment of ₹5.48 crore for the acquisition of 54,76,000 equity shares at par.
Final shareholding will be 15.91% on a fully diluted basis to maintain captive power status.
Target entity is developing a 27.12 MW (DC) solar power plant in Karnataka.
Strategic alignment with ESG goals to reduce carbon footprint and long-term energy expenses.
AMPIN reported a net worth of ₹120.78 million and a loss of ₹1.28 million for FY 2025-26.
👀 What to Watch
Investors should view this as a positive strategic move for operational efficiency and ESG compliance. While the investment size is small relative to Biocon's market cap, it secures long-term renewable energy and cost savings.
Concord Biotech Gets USFDA Approval for Tofacitinib Tablets; Targets $500M US Market
Concord Biotech has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Tofacitinib Tablets in 5 mg and 10 mg strengths. The drug is indicated for several chronic conditions, including rheumatoid arthritis and ulcerative colitis. The estimated U.S. market size for these specific strengths is approximately $500 million, representing a significant revenue opportunity. This approval is a key milestone in the company's strategy to expand its presence in the U.S. and international pharmaceutical markets.
Key Highlights
Received USFDA approval for Tofacitinib Tablets in 5 mg and 10 mg strengths
Addresses a U.S. market opportunity estimated at approximately $500 million
Indicated for treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis
Strengthens the company's product portfolio and long-term growth strategy in the U.S. market
👀 What to Watch
This approval is a significant positive trigger for the stock as it opens up a large addressable market in the U.S. Investors should watch for the commercial launch timeline and subsequent market share gains.
Biocon Shareholders Approve CEO Appointment and Preferential Share Issuance
Biocon Limited has announced the successful passage of 10 key resolutions via postal ballot, including the formal appointment of Mr. Shreehas Pradeep Tambe as CEO & Managing Director. Shareholders also gave near-unanimous approval (99.99%) for the issuance of equity shares on a preferential basis for consideration other than cash. While all resolutions passed with the requisite majority, the revision of Executive Chairperson Kiran Mazumdar-Shaw's remuneration and the appointment of Dr. Arun Suresh Chandavarkar saw notable institutional dissent at 21.3% and 31.6% respectively. The board has been significantly strengthened with the induction of several high-profile independent directors.
Key Highlights
Appointment of Mr. Shreehas Pradeep Tambe as CEO & MD approved with 94.37% total votes in favour.
Preferential issuance of equity shares for non-cash consideration passed with 99.99% shareholder support.
Revision in remuneration for Executive Chairperson Kiran Mazumdar-Shaw approved despite 21.3% institutional votes against.
Appointment of Dr. Arun Suresh Chandavarkar as Independent Director saw the highest total dissent at 11.9% of total votes.
A total of 10 resolutions were passed, including the appointment of Nivruti Rai and Rajiv Malik to the board.
👀 What to Watch
Investors should take confidence in the formalization of leadership and the addition of experienced independent directors to the board. However, keep a watch for the specific details regarding the non-cash preferential share issuance to understand potential dilution or strategic acquisitions.
Panacea Biotec Joins €11.1M EU-Funded DENSTAR Project for DengiAll® Vaccine Licensure
Panacea Biotec has launched the DENSTAR project, a four-year initiative funded by an €11.1 million grant from the Global Health EDCTP3 JU, supported by the European Union. The project aims to advance the licensure of Panacea's tetravalent dengue vaccine, DengiAll®, in sub-Saharan Africa and facilitate its broader global use. As a key partner in a 10-member international consortium, Panacea will participate in Phase I/III studies to confirm vaccine safety and efficacy in African populations. The vaccine is designed as a single-dose, cost-efficient solution that does not require prior serological testing, positioning it for large-scale deployment in low- and middle-income countries.
Key Highlights
Launch of the 48-month DENSTAR project starting June 1, 2026, to advance DengiAll® vaccine licensure.
Project funded by a €11,091,138.75 grant from the Global Health EDCTP3 JU, supported by the European Union.
Consortium includes 10 partners from 9 countries, including the University of Siena and Johns Hopkins University.
DengiAll® is a single-dose tetravalent vaccine currently in late-stage development in India.
The project will conduct Phase I/III studies in Africa and evaluate efficacy against DENV-4 using Controlled Human Infection Models.
👀 What to Watch
Investors should monitor the progress of clinical trials in Africa and the regulatory timeline for DengiAll® in India, as successful licensure could open significant global markets. The external funding reduces the financial burden of R&D for this specific project.
Concord Biotech FY26 PAT Drops 30% to ₹260 Cr; Management Guides for >18% Growth in FY27
Concord Biotech reported a challenging FY26 with total revenue declining 12% to ₹829 crores and PAT falling 30% to ₹260 crores, primarily due to geopolitical headwinds and supply chain disruptions in the Middle East and Europe. Despite the decline, the company maintained a healthy adjusted EBITDA margin of 39% and remains debt-free with ₹414 crores in cash. Management has provided a positive outlook for FY27, expecting growth to exceed their historical 18% average as supply issues normalize and new facilities scale up.
Key Highlights
FY26 Revenue declined 12% YoY to ₹829 crores, with Q4 witnessing a sharper 24% degrowth.
Profit After Tax (PAT) for the full year stood at ₹260 crores, down 30% compared to the previous fiscal.
Adjusted EBITDA margin (excluding new facility expenses) remained strong at 39%, though reported margin was 35%.
Management guides for FY27 growth to be higher than the historical 18% average, supported by a strong H1 visibility.
The company is debt-free with ₹414 crores in cash and has a peak revenue potential of ₹3,000 crores from existing units.
👀 What to Watch
Investors should focus on Q1 FY27 performance to confirm the management's turnaround guidance. While FY26 was impacted by temporary external factors, the company's strong balance sheet and new injectable/US subsidiary platforms provide a base for recovery.
IFB Industries to Host Q4 and FY26 Earnings Call on June 10, 2026
IFB Industries Limited has scheduled a conference call for June 10, 2026, at 4:00 PM IST to discuss its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The call will be hosted by Nirmal Bang Institutional Equities and will feature top management, including the Chairman and the MD & CEO of the Home Appliances Division. This session provides an opportunity for institutional investors and analysts to seek clarity on the company's operational performance and segment-wise growth.
Key Highlights
Conference call scheduled for June 10, 2026, at 16:00 IST following the Q4 and FY26 results.
Management representation includes Chairman Bikramjit Nag and MD & CEO Sandeep Joseph Abraham.
Discussion will cover both Standalone and Consolidated Audited Financial Results for the period ending March 31, 2026.
Dial-in details provided for multiple international jurisdictions including USA, UK, Singapore, and Hong Kong.
👀 What to Watch
Investors should attend or review the transcript of the call to understand management's outlook on raw material costs and demand trends in the Home Appliances and Engineering segments.
